These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 12198731)

  • 21. Inflammatory bowel diseases. Preface.
    Stange EF
    Dig Dis; 2013; 31(3-4):269. PubMed ID: 24246973
    [No Abstract]   [Full Text] [Related]  

  • 22. Host-bacterial interactions in inflammatory bowel disease.
    Mahida YR; Rolfe VE
    Clin Sci (Lond); 2004 Oct; 107(4):331-41. PubMed ID: 15212627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mucosal flora in inflammatory bowel disease.
    Swidsinski A; Ladhoff A; Pernthaler A; Swidsinski S; Loening-Baucke V; Ortner M; Weber J; Hoffmann U; Schreiber S; Dietel M; Lochs H
    Gastroenterology; 2002 Jan; 122(1):44-54. PubMed ID: 11781279
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Human inflammatory bowel disease does not associate with Lawsonia intracellularis infection.
    Michalski CW; Di Mola FF; Kümmel K; Wendt M; Köninger JS; Giese T; Giese NA; Friess H
    BMC Microbiol; 2006 Sep; 6():81. PubMed ID: 16984651
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nucleotide-binding-oligomerization domain proteins and toll-like receptors: sensors of the inflammatory bowel diseases' microbial environment.
    Mueller T; Podolsky DK
    Curr Opin Gastroenterol; 2005 Jul; 21(4):419-25. PubMed ID: 15930981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cell biology of the intestinal epithelium and its relation to inflammatory bowel disease.
    Deuring JJ; de Haar C; Kuipers EJ; Peppelenbosch MP; van der Woude CJ
    Int J Biochem Cell Biol; 2013 Apr; 45(4):798-806. PubMed ID: 23291352
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Reduced immunostaining for c-kit receptors in mucosal mast cells in inflammatory bowel disease.
    Farhadi A; Keshavarzian A; Fields JZ; Jakate S; Shaikh M; Banan A
    J Gastroenterol Hepatol; 2007 Dec; 22(12):2338-43. PubMed ID: 17645464
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Platelets: new players in the mucosal scenario of inflammatory bowel disease.
    Danese S; Scaldaferri F; Papa A; Pola R; Sans M; Gasbarrini G; Pola P; Gasbarrini A
    Eur Rev Med Pharmacol Sci; 2004; 8(5):193-8. PubMed ID: 15638229
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Microbial influences in inflammatory bowel diseases.
    Sartor RB
    Gastroenterology; 2008 Feb; 134(2):577-94. PubMed ID: 18242222
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Sulfide as a Mucus Barrier-Breaker in Inflammatory Bowel Disease?
    Ijssennagger N; van der Meer R; van Mil SWC
    Trends Mol Med; 2016 Mar; 22(3):190-199. PubMed ID: 26852376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular interactions between bacteria, the epithelium, and the mucosal immune system in the intestinal tract: implications for chronic inflammation.
    Clavel T; Haller D
    Curr Issues Intest Microbiol; 2007 Sep; 8(2):25-43. PubMed ID: 17542334
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intestinal oxidative damage in inflammatory bowel disease: semi-quantification, localization, and association with mucosal antioxidants.
    Kruidenier L; Kuiper I; Lamers CB; Verspaget HW
    J Pathol; 2003 Sep; 201(1):28-36. PubMed ID: 12950014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chronic inflammatory intestinal diseases. When the intestinal mucosa becomes thin].
    Lenzen-Schulte M
    Dtsch Med Wochenschr; 2005 Oct; Suppl 1():38-40. PubMed ID: 16379235
    [No Abstract]   [Full Text] [Related]  

  • 34. Clinical evidence for immunomodulatory effects of probiotic bacteria.
    Ruemmele FM; Bier D; Marteau P; Rechkemmer G; Bourdet-Sicard R; Walker WA; Goulet O
    J Pediatr Gastroenterol Nutr; 2009 Feb; 48(2):126-41. PubMed ID: 19179874
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Detection of Helicobacter species DNA by quantitative PCR in the gastrointestinal tract of healthy individuals and of patients with inflammatory bowel disease.
    Huijsdens XW; Linskens RK; Koppes J; Tang YL; Meuwissen SG; Vandenbroucke-Grauls CM; Savelkoul PH
    FEMS Immunol Med Microbiol; 2004 May; 41(1):79-84. PubMed ID: 15094170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases I. Pathophysiological basis and prospects for probiotic therapy in inflammatory bowel disease.
    Shanahan F
    Am J Physiol Gastrointest Liver Physiol; 2005 Mar; 288(3):G417-21. PubMed ID: 15701620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Microbial-epithelial cell crosstalk during inflammation: the host response.
    Kagnoff MF
    Ann N Y Acad Sci; 2006 Aug; 1072():313-20. PubMed ID: 17057211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Gut microbiota: mining for therapeutic potential.
    O'Hara AM; Shanahan F
    Clin Gastroenterol Hepatol; 2007 Mar; 5(3):274-84. PubMed ID: 17368226
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Paneth cells: their role in innate immunity and inflammatory disease.
    Elphick DA; Mahida YR
    Gut; 2005 Dec; 54(12):1802-9. PubMed ID: 16284290
    [No Abstract]   [Full Text] [Related]  

  • 40. Microecology as a target for therapeutic intervention in inflammatory bowel disease.
    Guarner F
    IDrugs; 2003 Sep; 6(9):868-73. PubMed ID: 12964066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.